Send the following on WhatsApp
Continue to Chathttps://it.marketscreener.com/quotazioni/azione/MERCK-CO-INC-13611/attualita/Merck-inizia-la-sperimentazione-clinica-di-Fase-3-di-MK-1084-un-inibitore-orale-sperimentale-di-KRA-46367892/?utm_source=whatsapp&utm_medium=social&utm_campaign=share